Serentrix
- Biotech or pharma, therapeutic R&D
PharmaCatalyst: Backing Breakthroughs from Day One
PharmaCatalyst is a seasoned group of angel investors focused on high-impact seed-stage biotech. Our track record includes successful exits in JDP Therapeutics, Sciformix, and AgriKind.
Our current portfolio company, Serentrix, is advancing SER014—a Phase 2–ready TRPV1 antagonist with clinical proof-of-concept in Dry Eye, Pain, and IBS.
At BIO2025, we’re actively seeking strategic partners to help unlock the full potential of this differentiated pain therapy.
Let’s connect.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}